Heartseed, Inc. (219A) Price & Analysis

Compare

4 Followers

219A Stock Chart & Stats

¥1804.00

-¥95.00(-2.73%)

At close: Jan 08 4:00 PM EST

¥1804.00

-¥95.00(-2.73%)

Day’s Range― - ―

52-Week Range¥1,343.00 - ¥4,385.00

Previous CloseN/A

Volume1.41M

Average Volume (3M)738.74K

Market Cap

¥42.49B

Enterprise Value¥35.50B

Total Cash (Recent Filing)¥7.34B

Total Debt (Recent Filing)¥890.00K

Price to Earnings (P/E)65.9

Beta1.18

Next Earnings

Jun 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding22,858,200

10 Day Avg. Volume469,170

30 Day Avg. Volume738,736

Financial Highlights & Ratios

PEG Ratio-0.38

Price to Book (P/B)5.16

Price to Sales (P/S)12.91

P/FCF Ratio37.15

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-130.4

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Return To Positive Cash FlowFY2025’s shift to sustained positive operating and free cash flow indicates the company can internally fund operations and reinvest in R&D and commercialization without near‑term capital raises. Predictable cash generation materially lowers funding risk and supports long‑term program continuity.

Very Low Leverage Balance SheetExtremely low leverage provides durable financial flexibility, reducing insolvency risk and enabling the firm to support lengthy clinical programs or frontload commercial investments. A conservative balance sheet is a lasting buffer through biotech funding cycles and operational setbacks.

Revenue And Margin ExpansionThe sharp FY2025 revenue increase alongside ~23% EBIT and ~20% net margins demonstrates the business can scale revenue with healthy unit economics. If persistent, this improved margin profile enhances capital efficiency, supports R&D funding, and signals a more sustainable commercial model.

Bears Say

Prior Multi-year Losses And Cash BurnA multi‑year history of steep losses and cash burn means FY2025’s improvement must be sustained to be durable. The company remains vulnerable to reversals that could force dilution or debt financing; past funding dependence signals structural risk until multi‑year cash generation is proven.

Inconsistent Gross Profit ReportingIrregular gross profit disclosure and an anomalous zero gross profit reading in FY2025 weaken confidence in reported margin trends. This opacity complicates forecasting and makes it harder to assess whether profitability is driven by structural operating improvement or accounting/one‑time factors.

Earnings Volatility & Execution RiskThe swing from multi‑year losses to a single profitable year reveals meaningful execution and outcome risk. For a medical/pharma company, continued commercialization, clinical outcomes, and operational scaling must succeed repeatedly for gains to persist, making future earnings uncertain.

Heartseed, Inc. News

Heartseed revamps governance with new executive officer system and board changes

Heartseed, Inc. ( ($JP:219A) ) has provided an update. Heartseed Inc. announced it will introduce an executive officer...

22d ago

219A

Heartseed Issues Cautionary Notice Alongside FY2025 Financial Results

Heartseed, Inc. ( ($JP:219A) ) has shared an announcement. Heartseed Inc. has released an informational document presenting its...

1M ago

219A

Heartseed Swings to Profit in 2025 but Signals Return to Loss on Higher 2026 Investment

Heartseed, Inc. ( ($JP:219A) ) has provided an update. Heartseed Inc. reported non-consolidated net sales of ¥3,026 million...

1M ago

219A

Heartseed Inc. Revises Financial Forecast with Positive Outlook

Heartseed, Inc. ( ($JP:219A) ) has provided an announcement. Heartseed Inc. announced a revision of its full-year financial...

3M ago

219A

Heartseed Inc. Reports Strong Financial Recovery

Heartseed, Inc. ( ($JP:219A) ) has issued an announcement. Heartseed Inc. reported significant financial improvement for the twelve...

3M ago

219A

Heartseed, Inc. Advances Cardiac Therapy Trial After Regulatory Approval

Heartseed, Inc. ( ($JP:219A) ) has shared an announcement. Heartseed, Inc. announced the completion of a 30-day review...

4M ago

219A

Heartseed Inc. Addresses Partnership Termination and Future Strategies

An update from Heartseed, Inc. ( ($JP:219A) ) is now available. Heartseed Inc. announced the termination of its...

6M ago

219A

Heartseed Inc. Advances Cardiac Therapy with New Clinical Trial Submission

The latest announcement is out from Heartseed, Inc. ( ($JP:219A) ). Heartseed Inc. has announced the submission of...

6M ago

219A

Heartseed, Inc. Ends Partnership with Novo Nordisk, Maintains Development Plans

Heartseed, Inc. ( ($JP:219A) ) has provided an update. Heartseed, Inc. announced the termination of its partnership with...

6M ago

219A

Heartseed Inc. Ends Partnership with Novo Nordisk, Shifts Focus to Japan

Heartseed, Inc. ( ($JP:219A) ) has shared an announcement. Heartseed Inc. announced the termination of its exclusive worldwide...

6M ago

219A

219A FAQ

What was Heartseed, Inc.’s price range in the past 12 months?

Heartseed, Inc. lowest stock price was ¥1343.00 and its highest was ¥4385.00 in the past 12 months.

What is Heartseed, Inc.’s market cap?

Heartseed, Inc.’s market cap is ¥42.49B.

When is Heartseed, Inc.’s upcoming earnings report date?

Heartseed, Inc.’s upcoming earnings report date is Jun 11, 2026 which is in 85 days.

How were Heartseed, Inc.’s earnings last quarter?

Currently, no data Available

Is Heartseed, Inc. overvalued?

According to Wall Street analysts Heartseed, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Heartseed, Inc. pay dividends?

Heartseed, Inc. does not currently pay dividends.

What is Heartseed, Inc.’s EPS estimate?

Heartseed, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Heartseed, Inc. have?

Heartseed, Inc. has 22,858,200 shares outstanding.

What happened to Heartseed, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Heartseed, Inc.?

Currently, no hedge funds are holding shares in JP:219A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Heartseed, Inc.

Heartseed, Inc. engages in the provision of cardiac regenerative medicine. The company was founded by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa and Yutaro Kasai on November 30, 2015 and is headquartered in Tokyo, Japan.